Commentary
See article on page 251Hepatocellular carcinoma: is surveillance cost effective?
| The first 150 words of the full text of this article appear below. |
The development of hepatocellular carcinoma
(HCC) constitutes a frequent event during the evolution of patients
with liver cirrhosis (3-5% annual incidence rate) and constitutes
their main cause of death.1 Survival is related to tumour
stage at diagnosis and to the degree of impairment of liver function.
Recent data have shown thatsurvival after diagnosis is not
as poor as reported years ago.2 This is due both to
advances in diagnosis even in the absence of effective treatment (lead
time bias) and to the application of curative treatments (surgical
resection, liver transplantation, and percutaneous
ablation).2 These offer the only chance of cure but their
applicability and long term success with five year survival exceeding
50% require the detection of HCC at an early stage, including patients
with solitary nodules 
5 cm or up to three nodules each 3
cm.2-5 In contrast, large/multifocal tumours are less
likely to benefit from curative approaches and
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Relevant Article
- Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis
- L Bolondi, S Sofia, S Siringo, S Gaiani, A Casali, G Zironi, F Piscaglia, L Gramantieri, M Zanetti, and M Sherman
Gut 2001 48: 251-259.[Abstract] [Full Text] [PDF]
This article has been cited by other articles:
-
Archer, K. J., Mas, V. R., David, K., Maluf, D. G., Bornstein, K., Fisher, R. A.
(2009). Identifying Genes for Establishing a Multigenic Test for Hepatocellular Carcinoma Surveillance in Hepatitis C Virus-Positive Cirrhotic Patients. Cancer Epidemiol. Biomarkers Prev.
18: 2929-2932
[Abstract] [Full Text] -
Shen, Z., Yang, Z. F., Gao, Y., Li, J. C., Chen, H. X., Liu, C. C., Poon, R. T.P., Fan, S. T., Luk, J. M., Sze, K. H., Li, T. P., Gan, R. B., He, M. L., Kung, H. F., Lin, M. C.M.
(2008). The Kringle 1 Domain of Hepatocyte Growth Factor Has Antiangiogenic and Antitumor Cell Effects on Hepatocellular Carcinoma. Cancer Res.
68: 404-414
[Abstract] [Full Text] -
Yuen, M.-F., Lai, C.-L.
(2003). Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol
14: 1463-1467
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Alert me when this article is cited
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
